Real-World Effectiveness of Nirmatrelvir–Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study - Takeaways - MDSpire

Real-World Effectiveness of Nirmatrelvir–Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study

  • By

  • Raymond N Kuo

  • Wanchi Chen

  • Wen-Yi Shau

  • Shan-Chwen Chang

  • September 2, 2025

  • 0 min

Share

  • 1

    Nirmatrelvir–ritonavir significantly reduced the risk of severe COVID-19 outcomes in Taiwan, including hospitalization and death.

  • 2

    The study analyzed data from 2,300,131 nonhospitalized COVID-19 patients, with 530,807 receiving nirmatrelvir–ritonavir.

  • 3

    Treatment with nirmatrelvir–ritonavir was most effective in unvaccinated individuals and those aged 65 years or older with risk factors.

  • 4

    The effectiveness of nirmatrelvir–ritonavir was consistent across various age groups and vaccination statuses.

  • 5

    Findings support the clinical value of early antiviral treatment to mitigate severe COVID-19 outcomes in vulnerable populations.

Original Source(s)

Real-World Effectiveness of Nirmatrelvir–Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study

  • by Raymond N Kuo, Wanchi Chen, Wen-Yi Shau, Shan-Chwen Chang

  • September 2, 2025

Related Content

Explainable machine learning-based mortality risk stratification for older adults with COVID-19: pinpointing core immunological biomarkers and revealing dose-threshold effects

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Assessing the association of physical distancing to avoid COVID-19 with health-related quality of life in immunocompromised adolescents: results from the cross-sectional observational EAGLE study